Duchenne muscular dystrophy cell therapy - CHUL Research Center

Drug Profile

Duchenne muscular dystrophy cell therapy - CHUL Research Center

Latest Information Update: 29 Sep 2015

Price : $50

At a glance

  • Originator CHUL Research Center
  • Class Cell therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Muscular dystrophies

Most Recent Events

  • 29 Sep 2015 Clinical development is ongoing in Canada
  • 06 Feb 2009 This programme is in active development in Canada
  • 21 Jun 2005 Phase-I/II clinical trials in Muscular dystrophy in Canada (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top